Genetic mutations or polymorphisms and altered signaling or expression of PPARG has been associated with decreased insulin action, obesity, dyslipidemia, as well as cardiovascular disease and cancer [31]. Here, PPARG is linked to obesity due to melanocortin 4 receptor deficiency.